FindTrial
Sign In

Evaluation of a novel integrated screening and diagnosis program for colorectal cancer in a large population

Evaluation of a novel integrated screening and diagnosis program for colorectal cancer in a large population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070520
Enrollment
Unknown
Registered
2023-04-14
Start date
2021-11-04
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Phase I Screening and fecal DNA methylation test group:N/A

Sponsors

Wuhan Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 45-60 (inclusive); 2. Able to read, understand and sign informed consent; 3. The investigator believes that the subjects understand the clinical study procedures, are willing and able to complete all study procedures and follow-up visits, and cooperate with the study procedures.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Detection rate of fecal DNA methylation test in colorectal cancer and precancerous lesions;—

Secondary

MeasureTime frame
Colonoscopy compliance rate ;Cost-benefit analysis of the integrated screening and diagnosis program;Positive predictive value of fecal DNA methylation test;Association of intestinal flora with colorectal cancer/precancerous lesions;Characteristics of urinary metabolites in patients with colorectal cancer/precancerous lesions;—

Countries

China

Contacts

Public ContactShi Zhaohong

Wuhan Hospital of Integrated Traditional Chinese and Western Medicine (Wuhan NO.1 Hospital)

zhaohshi@126.com+86 027-85332319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026